A Real-World Retrospective Cohort Study on the Clinical Effect of Silymarin (Legalon) on Liver Damage and Diseases Using a Domestic Multicenter Common Data Model.

Gut Liver · 2026 · PMC13180515 · PMID 40708304

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a decreasing trendno p-value reported

As a result, patients who were prescribed Legalon for ≥6 months showed a decreasing trend in AST, ALT, and ALP levels at both 3- and 6-month follow-up points in both the MASLD-diagnosed group (target group) and non-diagnosed group (control group).

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.